I think there are several things we don’t know based on the Press release..are the meeting with the three entities different meeting or collaborative to work thru distribution between countries or are they individual with Cytodyn.
Second, I posted a thought process a few weeks back saying it’s very possible Cytodyn has not looked at the data to stay “ clean” from being on the clock with the SEC , instead waiting for the meetings with the 3 agencies who have received the unblinded data in discussions now. Also waiting for the completed report to see all of the pertinent information.. I base this on NP comment about not knowing about mortality rates until the report is produced. I believe the PR makes reference to the report as well as discussion content being available within the 2-3 week timeframe. It’s counter intuitive to think a CEO would choose to go that route about when to review the data but getting information from the agencies ( which still may be at a high level on “what if’s” and not talking about a complete breakdown of the information) so if the final data read out is what the three agencies and Cytodyn expect to be true and plans can kick off immediately and joint press releases from 3 countries and Cytodyn are in synch . So the net would be, these meetings are planning , manufacturing distribution , and possibly funding meetings with the end product being the master plan and the final report..